Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Anticancer Res ; 37(11): 6347-6353, 2017 11.
Article in English | MEDLINE | ID: mdl-29061819

ABSTRACT

BACKGROUND: Feasibility and efficacy of boric acid (BA)-mediated boron neutron capture therapy (BNCT) was first demonstrated by eliminating hepatocellular carcinoma (HCC) in a rat model. Furthermore, selective uptake of BA by liver tumor cells was shown in a rabbit model. To gain further insight, this study aimed to investigate the mechanisms of transportation and selective uptake of BA in HepG2 liver tumor cells. MATERIALS AND METHODS: Transportation of BA in HepG2 cells was analyzed by time-course assays and by analyzing the rate of diffusion versus the concentration of BA. The effect of different tumor conditions on BA uptake was studied by treating HepG2 cells with 25 µg 10B/ml BA under different concentrations of glucose, at different pH and in the presence of water-soluble cholesterol. RESULTS: HepG2 cells mainly uptake BA by simple diffusion. Cell membrane permeability may also contribute to tumor-specific uptake of BA. CONCLUSION: The selective uptake of BA was achieved primarily by diffusion, while other factors, such as low pH and increased membrane fluidity, which are hallmarks of HCC, might further enhance BA uptake.


Subject(s)
Boric Acids/pharmacokinetics , Carcinoma, Hepatocellular/metabolism , Liver Neoplasms/metabolism , Tumor Microenvironment/radiation effects , Boric Acids/pharmacology , Boron Neutron Capture Therapy , Carcinoma, Hepatocellular/radiotherapy , Cell Membrane/ultrastructure , Cholesterol/pharmacology , Glucose/pharmacology , Hep G2 Cells , Humans , Hydrogen-Ion Concentration , Liver Neoplasms/radiotherapy , Spectrophotometry, Atomic
SELECTION OF CITATIONS
SEARCH DETAIL
...